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Abstract The 14 kDa protein was purified from human 
platelets. It displays high cytotoxic activity to the human ACL 
cells at 10 M concentration (21.8 ±7.1%). Its N-terminal 
sequence is YAPQXQFGP- , being highly homologous to region 
241-249 residues of the human Cls complement component. 
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1. Introduction 
H u m a n platelets take part in immune response processes. 
They initiate cytolysis of endotheliocytes [1,2] and autologous 
cytolysis of red blood cells [3]. In addition, they have IgE-, 
IgG-cytokine-dependent cytotoxicity against microorganisms 
[4,5] and are cytotoxic to human cancerous cells like other 
cells in the immune system [6,7]. For example, human platelets 
possess high specific cytotoxicity to A C L cells [8]. The cancer-
ous cells have thrombospondine adhesion domain receptors 
on the cell membrane [9]. Interleukines and other endogenic 
immune response modifiers stimulating platelet aggregation 
also induce platelet cytotoxicity [10,11]. The platelet activation 
factor (PAF) stimulating bioactive substances released from 
secretion granules of blood plates increases the platelet cyto-
toxicity activity at concentrations ranging from 10~12 to 10~6 
M [7]. All this suggests that some cytotoxic protein mediators 
are located within human platelets. Our paper deals with pu-
rification of these proteins and determination of their N-ter-
minal sequences. 
2. Materials and methods 
2.1. Preparation of platelets 
Venous blood (1000 ml) containing heparin (15 ml/ml) taken from 
healthy donors was centrifuged at 200 Xg for 10 min. Blood plasma 
enriched with platelets was centrifuged at 400Xg for 10 min. The 
sediment containing platelets was resuspended in the RPMI-1640 
cell culture medium, then twice centrifuged at lOOOXg for 10 min 
to remove serum proteins. The platelet sediment was stored at —70°C. 
2.2. Preparation of supernatant of platelets 
The platelet sediment was resuspended in buffer containing 0.1% 
TFA, 2 M NaCl, then frozen and thawed 3 times for cell membrane 
destruction. Cell debris and unbroken cells were centrifuged at 
5000Xg for 30 min for removal. 
*Corresponding author. Fax: (7) 95-3357103. 
E-mail: Victor@siobc.ras.ru 
Abbreviations: ACL, adenocarcinoma cell line; PAF, platelet activa-
tion factor; TFA, trifluoroacetic acid; SDS, sodium dodecyl sulfate; 
PAGE, polyacrylamide gel electrophoresis; RP-HPLC, reverse-phase 
high-performance liquid chromatography; MTT, 3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl tetrazolium bromide; PVDF, polyvinylidene 
difluoride 
2.3. Protein purification 
The supernatant was immediately applied to the C4 column (Hi 
Pore RP-304, Bio-Rad, 4.6X250 mm), equilibrated with 0.1% TFA 
and eluted with the 60-min linear acetonitrile gradient from 0 to 90%. 
The flow rate was 1 ml/min; UV detection wavelength was 220 nm. 
Each peak aliquot (50 ml) was tested to establish cytotoxic activity. 
The fractions were lyophilized and stored at —4°C. 
Active fractions were analyzed by SDS-PAGE (12%) according to 
Laemmli [12]. The proteins were electroblotted on the Immobilon-P 
membrane using a semi-dry procedure in 0.02 M sodium bicarbonate 
buffer at 1 mA/sm current density for 1.5 h. They were then developed 
by Coomassie R-250 staining. 
To measure protein the PVDF membrane was scanned by Ultraspec 
2202 laser densitometer (LKB) at 600 nm. 
2.4. MTT cytotoxicity assay 
Aliquots of HPLC fractions were lyophilized, resuspended in 100 
ml of RPMI-1640 cell culture medium and incubated with 5% C0 2 at 
37°C for 18 h. MTT cytotoxicity assay was performed according to 
[13], The cytotoxicity (C, %) was counted with the equation: 
C=[(ODC-ODCX)/ODC]X100%. Here, ODcx is the optical density of 
the experimental solution and ODc of the control solution. 
The statistic method [14] was applied to analyse the results of the 
five identical experiments. 
The cytotoxicity of certain proteins was measured after elution of 
protein band from the PVDF membrane as described by Chertov et 
al. [15]. 
2.5. Amino acid sequence determination 
Amino acid sequencing was performed from the PVDF membrane 
using a Model 470A Applied Biosystems gas-phase sequencer. 
3. Results 
We obtained 15 fractions from R P - H P L C of the superna-
tant containing human platelets (Fig. 1). The fractions were 
tested to establish the cytotoxicity to the A C L target cells. 
Fraction 5 eluted from 33 to 36% of acetonitrile demonstrated 
the highest cytotoxicity (24.1 ±7.4%) (Fig. 2). 
We observed only one band of 14 k D a protein (pi4) after 
separating this fraction by SDS-PAGE. According to densito-
metric analysis of the p l 4 SDS-PAGE band, 100 ml of plaque 
plasma contained more than 10 pmol of p i 4 . The protein was 
electroblotted and eluted from the P V D F membrane, its cy-
totoxicity was measured at various concentrations (Table 1), 
thus being inactive at a concentration of 10~8 M. The highest 
cytotoxicity was observed at 10~10 M (21.8 ±7.1%). 
The p l 4 N-terminal sequence appeared to be gomolog-
ous to region 241-249 residues of the human Cls comple-
ment component : p l 4 , - ' Y A P Q X Q F G P 9 - and Cls, 
- 2 4 1 V A G D R Q F G P 2 4 9 . 
4. Discussion 
The cytotoxic activity of human platelets has been described 
by many authors. Soper et al. [16] outlined the platelet's role 
in the mechanism of antibody-dependent cellular cytotoxicity. 
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Fig. 1. Elution profile of a human platelet extract (2 ml) on Hi 
Pore RP-304 column (250x4.6 mm, Bio-Rad). First eluent was 
0.1% TFA. The linear acetonitrile gradient ranged from 0 to 90% 
for 60 min. The flow rate was 1 ml/min. UV detection wavelength 
was 220 nm. 'Highest cytotoxic (21.8 ±7.1%) fraction. 
Shin et al. [17-19] showed that platelets were involved as 
effectors in the cytotoxic antibody-dependent immune re-
sponse in vivo. According to Slezak et al. [20] the antibody-
dependent cellular cytotoxicity system is arranged on the pla-
telet cell membrane because the supernatant obtained after 
platelet lysis and centrifugation showed much less activity 
against chicken erythrocytes than did the sediment containing 
platelet membranes. 
Ibele et al. [6] described the platelet cytotoxic action to the 
finite cell lines of kidney melanoma and adenocarcinoma. The 
supernatant obtained after incubation (5% CO2, 4 h, 37°C) of 
cytotoxicity,% 
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Fig. 2. Cytotoxic activity of HPLC fractions (Fig. 1) of the superna-
tant of human platelets. 
313 
Table 1 
Cytotoxic activity of pl4 
Concentration Cytotoxic activity Probability level 
10"8 M 6.3% ±6.8% >0.05 
10"10 M 21.8%±7.1% <0.05 
10~12 M 14.2% ±8.8% <0.05 
human platelets in multiwell plates containing the RPMI cell 
culture medium was cytotoxic to cancer cells. The platelets 
were activated after adhesion to the plate bottom and their 
granules with a cytotoxic factor were dissolved in the super-
natant. Our results confirmed data described by Ibele et al. 
However, the supernatant that we prepared was used to ob-
tain the cytotoxic protein by 3-fold freezing and thawing with 
subsequent centrifugation at 5000 Xg for 30 min. As shown by 
Slezak et al. [20] the platelet granules were completely dis-
solved in the supernatant. 
The 14 kDa protein that we purified displayed cytotoxic 
activity to the ACL cells in the absence of antibodies. How-
ever, its high homology to a region of the human Cls comple-
ment component still requires an explanation. 
According to Segava et al. [21] the platelets activated by 
thrombin and those nonactivated are cytotoxic to K-562 cells. 
The supernatant containing secret products of platelets acti-
vated by thrombin is not, however, cytotoxic to K-562 cells. 
This fact apparently indicated the specificity of the platelet 
cytotoxic factor action and the dependence on a target cell 
type. Different cytotoxic factors were probably involved in 
cytolysis of various target cells. In this case, the factor inves-
tigated by Segava et al. had a high lability and lost its activity 
in the supernatant. 
The above data testify to the existence of not less than two 
different mechanisms of platelet cytotoxicity: platelets (1) 
cause antibody-dependent cellular cytotoxicity with their me-
diators disposed on the platelet cell membrane and (2) display 
cytotoxic activity in the absence of antibodies, although this 
does not depend on the type of target cells and the cytotoxic 
factors are thus contained in platelet granules. 
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